BCOP Self-Study
These modules focus on literature published within the last two years. Participants will learn about new developments and cutting-edge findings through case-based discussions that help you apply the information presented.
Self Study 2024 Release II is now available - it contains 10 ACPE and BCOP CEs total.
On-demand Learning Opportunities
Clear filter
-
Bundle
Self Study 2024 Release II Bundle
On-demand The 2024 BCOP Self-Study Bundle Release II offers 10 BCOP CE hours and ACPE CE hours. Learn more -
Individual
Self Study 2024 Release II: Bispecific T-Cell Engager Therapy: Hematologic Malignancies and Solid Tumors
On-demand This module provides an overview of the evidence supporting their approved indications and discusses current recommendations and ongoing areas of research for this class of agents. Learn more -
Individual
Self Study 2024 Release II: Treatment Updates in Myelodysplastic Syndrome
On-demand In this module, participants will evaluate current and potential future treatment advances in the management of both lower- and higher-risk MDS. Learn more -
Individual
Self Study 2024 Release II: Adolescent/Young Adult Survivorship (Healthcare Disparities as well as Long-Term Mortality)
On-demand This module will explore the challenges faced by AYA survivors of cancer including physical, psychological, and social burdens, risk of comorbidity development, and factors influencing increased mortality and reduced survival. Learn more -
Individual
Self Study 2024 Release II: ESR1 Mutations in Metastatic Breast Cancer
On-demand Endocrine therapy is the backbone of treatment in hormone receptor (HR) positive, human epidermal growth factor receptor-2 (HER2) negative, metastatic breast cancer (mBC), but resistance universally develops. Our understanding of the role of mutations in the gene that encodes for the estrogen receptor, ESR1, in resistance to endocrine therapies has grown in the last 5 years. Patients acquire mutations in the ligand binding domain for ESR1 after treatment with endocrine therapy, leading to resistance to aromatase inhibitors. Learn more -
Individual
Self Study 2024 Release II: Neoadjuvant Immunotherapy Updates in NSCLC, Colon, and Rectal Cancer
On-demand Review updates for use of ICI in the neoadjuvant setting. This will include a review of safety and efficacy data of pembrolizumab in NSCLC, review of predictive biomarkers in rectal and colon cancer, and safety and efficacy data of dostarlimab in rectal cancer. Learn more -
Individual
Self-Study 2024 Release I: Updates in Uveal Melanoma
On-demand The purpose of this course is to review treatment options and updates in the management of uveal melanoma. Learn more -
Individual
Self-Study 2024 Release I: PARP Inhibitor Combination Regimens for mCRPC
On-demand Develop appropriate treatment and supportive care plans utilizing PARP inhibitor combination therapy for patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Learn more -
Individual
Self Study 2024 Release I: Ocular Toxicities with Antineoplastics
On-demand In this module, participants will explore various ocular adverse events associated with different classes of antineoplastics. Learn more -
Individual
Self Study 2024 Release I: Navigating Oncology Drug Shortages
On-demand This module will review literature exploring strategies to overcome recent drug shortages while also ensuring equity remains uncompromised for underserved patient populations in this public health crisis. Learn more -
Bundle
Self Study 2024 Release I Bundle
On-demand The 2024 BCOP Self-Study Bundle Release I offers 9 BCOP CE hours and ACPE CE hours. Learn more